| abstract |
Methods of treating hyperkinetic diseases and disorders, such as delayed dyskinesia, are provided. In certain embodiments, the potent VMAT2 inhibitor (+)α-3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1- a]Isoquinolin-2-ol ((+)α-HTBZ) is used in the methods described herein for treating a subject in need thereof. |